Danaher Corporation (NYSE:DHR) Holdings Raised by EFG Asset Management Americas Corp.

Key Points

• EFG Asset Management Americas Corp. increased its stake in Danaher Corporation by 13.1%, acquiring a total of 36,080 shares valued at approximately $7.4 million.
• Multiple institutional investors have also increased their holdings, including GHP Investment Advisors, which raised its stake by a significant 396%.
• Analysts have lowered Danaher's price targets, with a consensus rating of "Moderate Buy" and an average price target of $247.61, despite the company reporting earnings that exceeded estimates.

EFG Asset Management Americas Corp. increased its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 13.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,080 shares of the conglomerate's stock after purchasing an additional 4,191 shares during the period. Danaher accounts for about 1.5% of EFG Asset Management Americas Corp.'s holdings, making the stock its 18th biggest position. EFG Asset Management Americas Corp.'s holdings in Danaher were worth $7,396,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. MGO One Seven LLC raised its holdings in Danaher by 485.7% in the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock valued at $5,145,000 after acquiring an additional 20,813 shares during the last quarter. Sound View Wealth Advisors Group LLC increased its stake in Danaher by 3.9% in the first quarter. Sound View Wealth Advisors Group LLC now owns 1,807 shares of the conglomerate's stock valued at $370,000 after purchasing an additional 68 shares during the last quarter. North Star Asset Management Inc. lifted its position in Danaher by 3.6% during the first quarter. North Star Asset Management Inc. now owns 113,406 shares of the conglomerate's stock worth $23,248,000 after buying an additional 3,941 shares during the period. Woodley Farra Manion Portfolio Management Inc. lifted its position in Danaher by 3.8% during the first quarter. Woodley Farra Manion Portfolio Management Inc. now owns 243,080 shares of the conglomerate's stock worth $49,906,000 after buying an additional 8,893 shares during the period. Finally, Arkadios Wealth Advisors grew its holdings in Danaher by 39.6% in the 1st quarter. Arkadios Wealth Advisors now owns 4,685 shares of the conglomerate's stock valued at $960,000 after buying an additional 1,330 shares during the period. Hedge funds and other institutional investors own 79.05% of the company's stock.

Analyst Ratings Changes

DHR has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Barclays reissued an "overweight" rating and set a $225.00 price objective (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. UBS Group cut their target price on Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday, July 23rd. Leerink Partners boosted their price target on Danaher from $225.00 to $230.00 and gave the company an "outperform" rating in a research report on Wednesday, April 23rd. Finally, Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to data from MarketBeat, Danaher has a consensus rating of "Moderate Buy" and an average target price of $247.61.

Danaher Stock Performance

Danaher stock traded down $0.08 during mid-day trading on Friday, reaching $197.08. The company's stock had a trading volume of 5,736,543 shares, compared to its average volume of 4,375,955. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The business has a 50 day moving average price of $197.49 and a 200-day moving average price of $202.68. The firm has a market cap of $141.12 billion, a price-to-earnings ratio of 41.93, a PEG ratio of 2.74 and a beta of 0.73.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The firm had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. Danaher's revenue was up 3.4% on a year-over-year basis. During the same quarter last year, the company posted $1.72 earnings per share. Sell-side analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, July 25th. Shareholders of record on Friday, June 27th were given a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher's dividend payout ratio is presently 27.23%.

Insiders Place Their Bets

In other news, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the sale, the chairman owned 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 11.10% of the stock is owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.